Abstract Library

#4637 Non-functional retroperitoneal paraganglioma in a young patient: A case report

Introduction: Paragangliomas are neuroendocrine tumours arising in the parasympathetic nervous system, outside the adrenal gland. Retroperitoneal location is extremely rare. Non-functional paragangliomas often represent a diagnostic challenge.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: retroperitoneal paraganglioma, surgery, monitoring,

#4612 Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial

Introduction: Accurate localisation of gastroenteropancreatic neuroendocrine tumours (GEP-NET) is essential for successful radical surgery. Radio guided surgery (RGS) is an innovative technique that may enhance lesion detection.

Conference:

Presenting Author: Bertani E

Authors: Bertani E, Fumagalli Romario U, Collamati F, Ferrari M, Mattana F,

Keywords: radio guided surgery, surgery, neuroendocrine tumour, GEP-NET, gastrointestinal tumour,

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4505 NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies

Introduction: Previously, we showed that analysing copy number alterations (CNAs) in cell-free DNA (cfDNA) of NET patients using shallow whole genome sequencing (sWGS) is a potential biomarker for diagnosis and follow-up (PMID: 34759042). We now present NET-IMPRESS, an easy, cost-effective methylation-based assay for detecting circulating tumour DNA (ctDNA) in NET samples.

Conference:

Presenting Author:

Authors: Mariën L, Ibrahim J, de Meulenaere N, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumour, liquid biopsy, DNA methylation, copy number alterations, biomarker selection, IMPRESS technology,